Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and olaparib

irinotecan has been researched along with olaparib in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (72.73)24.3611
2020's3 (27.27)2.80

Authors

AuthorsStudies
Kanomata, N; Kozuka, Y; Kurebayashi, J; Moriya, T; Shimo, T; Sonoo, H; Yamashita, T1
Fujii, H; Horie, H; Inoue, T; Kotake, K; Miyakura, Y; Sato, F; Sugano, K; Tahara, M; Yasuda, Y1
Bahrami, A; Benavente, C; Bradley, C; Calabrese, C; Caufield, W; Dyer, MA; Freeman, BB; Gordon, B; Goshorn, R; Griffiths, LM; Hatfield, MJ; Karlström, Å; Loh, A; Miller, GM; Pappo, A; Potter, PM; Sablauer, A; Shelat, AA; Shirinifard, A; Snyder, SE; Stewart, E; Thiagarajan, S; Tsurkan, L; Twarog, NR; Wu, J1
Chen, EX; Hagerman, L; Jonker, DJ; Keller, D; McKeever, K; Seymour, L; Siu, LL; Wells, J1
Azad, NS; De Jesus-Acosta, A; Donehower, RC; Fine, RL; Goggins, M; Jaffee, EM; Johnson, BA; Laheru, DA; Le, DT; Myzak, MC; Oberstein, PE; Yarchoan, M; Zheng, L1
Barrett, JC; Cadogan, EB; Garcia-Trinidad, A; Griffin, N; Harrington, EA; Howat, WJ; Hughes, GD; Ivey, RG; Jones, GN; Lau, A; Odedra, R; Paulovich, AG; Pierce, AJ; Ramos-Montoya, A; Rooney, C; Roudier, M; Whiteaker, JR; Wilson, Z; Young, LA; Zhao, L1
Cao, D; Hou, S; Li, A; Li, M; Mou, Y1
Masuda, U; Matsumoto, A; Minegaki, T; Miyamoto, K; Moriyama, Y; Nishiguchi, K; Ota, K; Tanahashi, M; Tanaka, M; Tsujimoto, M; Wada, A; Yamamoto, A1
Abaei, A; Arnold, F; Barth, TFE; Beutel, AK; Gout, J; Kleger, A; Müller, M; Perkhofer, L; Rasche, V; Roger, E; Seufferlein, T1
Cepero, A; Martin-Guerrero, SM; Martin-Oliva, D; Melguizo, C; Munoz-Gamez, JA; Ortiz, R; Prados, J; Quinonero, F; Urbano, D1
Bargh-Dawson, H; Brown, E; Gerrard, J; Hughes, AM; Jones, GN; Lau, A; O'Connor, MJ; Odedra, R; Wallez, Y; Wijnhoven, PWG; Wilson, Z; Young, LA1

Trials

1 trial(s) available for irinotecan and olaparib

ArticleYear
A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
    Investigational new drugs, 2016, Volume: 34, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Phthalazines; Piperazines; Treatment Outcome

2016

Other Studies

10 other study(ies) available for irinotecan and olaparib

ArticleYear
Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Breast cancer (Tokyo, Japan), 2014, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Irinotecan; Neoplastic Stem Cells; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Receptor, ErbB-2

2014
The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:5

    Topics: Animals; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Irinotecan; Mice; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerases; Rad51 Recombinase; Tumor Burden; Xenograft Model Antitumor Assays

2014
Targeting the DNA repair pathway in Ewing sarcoma.
    Cell reports, 2014, Nov-06, Volume: 9, Issue:3

    Topics: Animals; Benzimidazoles; Camptothecin; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Enzyme Inhibitors; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sarcoma, Ewing; Temozolomide; Xenograft Model Antitumor Assays

2014
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.
    Oncotarget, 2017, Jul-04, Volume: 8, Issue:27

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Staging; Pancreatic Neoplasms; Phthalazines; Piperazines; Retreatment; Treatment Outcome

2017
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
    British journal of cancer, 2018, Volume: 119, Issue:10

    Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Biomarkers; Cell Line; DNA Damage; Humans; Immunohistochemistry; Indoles; Irinotecan; Mass Spectrometry; Mice; Mice, Nude; Morpholines; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinolines; Signal Transduction; Sulfonamides; Sulfoxides; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2018
Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
    Medicine, 2018, Volume: 97, Issue:45

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; BRCA2 Protein; Carcinoma, Acinar Cell; Drug Combinations; Fatal Outcome; Fluorouracil; Humans; Irinotecan; Laparotomy; Leucovorin; Male; Middle Aged; Mutation; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Phthalazines; Piperazines; Tomography, X-Ray Computed

2018
Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines.
    Anticancer research, 2019, Volume: 39, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Esophageal Squamous Cell Carcinoma; Histones; Humans; Irinotecan; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide

2019
Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
    Cells, 2020, 09-16, Volume: 9, Issue:9

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chromosomal Instability; DNA Damage; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Maintenance Chemotherapy; Mice; Mice, Nude; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Survival Analysis; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays

2020
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
    Journal of biosciences, 2021, Volume: 46

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Irinotecan; Liver Neoplasms; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays

2021
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
    Cancer research, 2022, 03-15, Volume: 82, Issue:6

    Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carboplatin; Humans; Indoles; Irinotecan; Morpholines; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sulfoxides; Triple Negative Breast Neoplasms

2022